

### Amendments to the Claims

1. (Currently Amended) A transdermal preparation containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof as the sole active ingredient, and an external preparation base.
- 2-3. (Cancelled)
4. (Original) The preparation according to claim 1 for use as a prophylactic or therapeutic agent for preventing or treating a disorder in patients with overactive bladder, the disorder selected from increased urinary frequency, urinary incontinence, asthma, chronic airway obstruction, and irritable bowel syndrome.
5. (Original) The preparation according to claim 4, wherein the disorder is increased urinary frequency and urinary incontinence in patients with overactive bladder.
6. (Original) The preparation according to claim 1, provided in the form of patch.
7. (Original) The preparation according to claim 6, provided in the form of a single adhesive layer-type or a reservoir-type transdermal preparation.
8. (Currently Amended) The preparation according to claim 7, containing as ~~an active~~ sole active ingredient a dissolved form of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide alone.
9. (Currently Amended) The preparation according to claim 7, containing as sole active ingredients dissolved and non-dissolved forms of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.
10. (Cancelled)

11. (Currently Amended) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 1, containing as ~~an active~~ the sole active ingredient 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide and comprising an external preparation base and a structural body.

12. (Cancelled)

13. (Currently Amended) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a reservoir type, comprising:

a mixture of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the sole active ingredient and a single or combination of the external preparation bases; and

a structural body comprising a membrane for controlling drug permeation, an adhesive layer, a support, and a peelable liner.

14-16. (Cancelled)